November 19, 2025 — Leads & Copy — Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, has finalized an initial supply agreement with Yuanshuo Medical Instruments Corporation (YMIC) to purchase $200,000 worth of LuViva devices and single-use components.
YMIC, headquartered in Jiangsu province, China, is licensed by the Chinese government to sell and distribute Class II and Class III medical devices. Additional orders are anticipated next year under a broader supply agreement currently under discussion.
Mark Faupel, CEO of Guided Therapeutics, expressed enthusiasm about the new partnership, stating that they expect LuViva to find cervical cancer earlier and improve outcomes for the 137 million women who live in Jiangsu province.
The agreement with YMIC is in addition to Guided Therapeutics’ current agreement with Hangzhou Dongye Medical Technology Company, Ltd. (HDMT) to supply 35 devices. HDMT, located in Hangzhou City, Zhejiang Province, is the exclusive provider of gynecology products for 42 hospitals that perform approximately two million cervical cancer screenings annually.
Guided Therapeutics, Inc. (OTCQB: GTHP) is focused on developing a rapid and painless testing platform based on its patented biophotonic technology. The company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device designed for the early detection of cervical disease at the point of care. Clinical trials have indicated that the technology can detect cervical cancer up to two years earlier than conventional methods.
The Guided Therapeutics LuViva® Advanced Cervical Scan is currently limited to investigational use in the U.S. per federal law. LuViva and the wave logo are registered trademarks of Guided Therapeutics, Inc.
Forward-Looking Statements Disclaimer: This news release includes discussions of potential future circumstances and developments that are subject to inherent risks and uncertainties. Actual future experience may differ materially from current expectations due to factors such as the early stage of product commercialization, market acceptance, development of distribution channels, competition in the medical device industry, capital sufficiency, regulatory approval, and dependence on licensed intellectual property. These risks are detailed in Guided Therapeutics’ reports filed with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent filings.
Source: Guided Therapeutics, Inc.
